文献速递银屑病与炎症性皮肤病

JAK1抑制剂PF-04965842治疗中重度银屑病的II期随机双盲安慰剂对照研究

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
PubMed 文献 · Br J Dermatol · 2018-03-06

主要终点为第4周PASI较基线变化,结果显示各活性组均优于安慰剂,200mg每日两次组疗效最显著,且耐受性良好。

要点

  • PF-04965842各剂量组第4周PASI改善均优于安慰剂,200mg每日两次组效应最大。
  • 第4周PASI 75应答率:安慰剂和200mg每日一次组均为17%,400mg每日一次组50%,200mg每日两次组60%。
  • 200mg每日两次组中性粒细胞、网织红细胞和血小板降低的异常实验室结果多于每日一次组,但未报告相关严重感染或出血事件。

核心结论

  • PF-04965842可改善中重度斑块状银屑病症状且耐受性良好。

研究设计与样本

  • 研究因申办方开发优先级变更于2015年6月25日停止入组。

主要发现

  • 第4周达到PASI 75的患者比例:安慰剂组17%,200mg每日一次组17%,400mg每日一次组50%,200mg每日两次组60%。
  • 200mg每日两次组临床关注的异常实验室结果(中性粒细胞、网织红细胞和血小板计数降低)多于每日一次组。
  • 未报告与中性粒细胞减少或血小板减少相关的严重感染或出血事件。

临床怎么用

  • PF-04965842每日两次200mg方案在第4周显示更高PASI 75应答率,但需关注中性粒细胞、网织红细胞和血小板计数降低。

局限性

  • 治疗和观察期仅4周,缺乏长期疗效和安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PF-04965842 is an oral Janus kinase 1 inhibitor being investigated for the treatment of plaque psoriasis. OBJECTIVES: To evaluate the efficacy, safety and tolerability of PF-04965842 in patients with moderate-to-severe plaque psoriasis. METHODS: Patients in this phase II, placebo-controlled study (NCT02201524) were randomized to receive placebo, 200 mg once daily (OD), 400 mg OD or 200 mg twice daily (TD) PF-04965842 for 4 weeks. The primary endpoint was change from baseline in Psoriasis Area Severity Index (PASI) at week 4. Study enrolment was discontinued on 25 June 2015 due to changes in the sponsor's development priorities. RESULTS: Fifty-nine patients were randomized and received at least one dose of PF-04965842 or placebo. The estimated treatment effect (active -placebo PASI change from baseline) and 90% confidence interval at week 4 was -5·1 (-9·2 to -1·0), -5·6 (-9·6 to -1·6) and -10·0 (-14·2 to -5·8) for the 200 mg OD, 400 mg OD and 200 mg TD groups, respectively. At week 4, the proportion of patients achieving PASI 75 was 17% for the placebo and 200 mg OD groups, 50% for the 400 mg OD group and 60% for the 200 mg TD group. There were more abnormal laboratory test results of clinical interest (low neutrophil, reticulocyte and platelet counts) in the 200 mg TD group compared with the OD treatment groups. No serious infections or bleeding events related to neutropenia or thrombocytopenia, respectively, were reported. CONCLUSIONS: These results suggest that treatment with PF-04965842 improves symptoms and is well tolerated in patients with moderate-to-severe psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2018. PMID: 28949012. doi:10.1111/bjd.16004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。